Eng

How one man is giving hope and free HIV drugs to China’s coronavirus patients

South China Morning Post
發布於 2020年02月26日09:02 • Alice Yan ting.yan@scmp.com
  • Andy Li runs an online platform that lets people with extra medications share them with people in need
  • He says he knows from personal experience what it means to feel helpless in the face of a diagnosis
Despite legal risks, Andy Li from Zhengzhou, Henan province, distributes the HIV drug Kaletra, also known as Aluvia, to coronavirus patients for free. Phot: Andy Li

When Andy Li heard that Chinese health authorities had listed an HIV/Aids drug combination as a treatment for coronavirus patients, he knew he had to act.

Li, who works for his family's building materials company in Zhengzhou in central Henan province, is HIV-positive and the founder of a non-profit online drug distribution platform that enables fellow HIV carriers to share their leftover drugs with others when they run short.

廣告(請繼續閱讀本文)

Among the medications offered on the platform is a combination of lopinavir and ritonavir sold under the brand names Kaletra and Aluvia.

Kaletra is prescribed free to China's 958,000 HIV carriers, with health authorities typically giving patients 360 pills each for three months.

But Li said that some people did not take the medication because of side effects such as diarrhoea, and those who could afford it paid for other medicines out of their own pocket. Li's platform allows these people to give their unused drugs to others for free.

廣告(請繼續閱讀本文)

On January 27, China's National Health Commission released a clinical guideline saying that Kaletra was recommended as a treatment for mild cases of Covid-19 " the disease caused by the new coronavirus that has infected nearly 80,000 people and killed more than 2,500.

The next day, Li wrote on the Twitter-like service Weibo that he could send Kaletra pills to coronavirus patients for free.

He said he felt a common bond with those who came down with the disease and felt a responsibility to help them.

廣告(請繼續閱讀本文)

"As an HIV carrier, I empathise with them. I can understand their helplessness, fear and loneliness," Li said.

In the first few weeks after the announcement, requests from coronavirus patients flooded.

At the time, many people confirmed with the disease were not admitted by hospitals but still needed the medication. But it was also in short supply even for many who did get a hospital bed, according to Li.

"I expected there would be problems with supplies of Kaletra in many hospitals because they are not designated hospitals for HIV patients and don't have this drug in stock," Li said.

"The demand has dropped recently as the situation has improved and hospital operations in Wuhan and other cities have become less chaotic."

Over the weeks, Li and a team of five volunteers, took the orders, collected the medications from other people in the HIV-positive community and sent them off to the recipients. The volunteers include a doctor who is responsible for checking that the drug applicant's need is genuine.

"People with HIV responded warmly to my call for donations of the drug," he said. "We feel it is meaningful because the timely delivery of Kaletra to coronavirus patients could help cure their disease and reduce the number of people whose symptoms progressed from mild to serious."

Who owns the coronavirus cure? China's move to patent Gilead's experimental drug for the novel virus could lead to legal wrangle

At first, Li sent patients 60 pills each because the guideline in January stipulated that patients should take Kaletra twice a day, two pills at a time, but without saying how long it should be taken.

After the health commission updated the clinical guideline on February 19 that patients should take the medication for no more than 10 days, Li cut back the number to 40 pills per patient.

So far, about 220 people have received the drugs.

Li said patients needed a hospital document to show that they had the virus and a doctor's prescription to qualify for a shipment. He also said he asked each applicant to sign a letter taking all responsibility for any adverse effects of the drug.

But he is aware that there is still a risk of being sued if a recipient develops side effects.

A conviction for distributing drugs without a licence can also attract a sentence of up to five years in jail.

"It's my style " I won't hold back from doing something even if I see a risk," Li said.

In the meantime, the commission is collecting data from clinical trials of various treatments for the coronavirus, including the use of Kaletra.

However, a Shanghai-based infectious disease doctor said she was surprised that the authorities had not intervened in the platform's activities because Li did not appear to have a licence to distribute drugs.

"He is not a medical professional so he cannot guarantee each person gets the treatment they need and cannot guarantee that they are taking the drug in a safe way," the doctor said, declining to be named.

She said that medication might not be effective if not taken as designed.

Li said that so far no government department had sought to put a stop to the activity, which he said was motivated by good intentions.

"It's just that a group of patients help another group of patients," he said.

"If my actions can change public prejudice against HIV-positive people, that's good. But from the start, my goal has been just to help people."

Purchase the China AI Report 2020 brought to you by SCMP Research and enjoy a 20% discount (original price US$400). This 60-page all new intelligence report gives you first-hand insights and analysis into the latest industry developments and intelligence about China AI. Get exclusive access to our webinars for continuous learning, and interact with China AI executives in live Q&A. Offer valid until 31 March 2020.

Copyright (c) 2020. South China Morning Post Publishers Ltd. All rights reserved.

查看原始文章

更多 Eng 相關文章

China sees nearly 300 mln domestic tourist trips during May Day holiday
XINHUA
Earthquakes jolt Taiwan: CENC
XINHUA
Malawi launches soybean exports to China
XINHUA
Youdao to Report First Quarter 2024 Financial Results on May 23
PR Newswire (美通社)
ATRenew to Report First Quarter 2024 Financial Results on May 20, 2024
PR Newswire (美通社)
GLOBALink | Participation in BRI boosts Serbia's overall development: minister
XINHUA
Global Times: Former French PM Raffarin signals high hopes for President Xi's visit, emphasizes respect for civilizations, frank dialogue
PR Newswire (美通社)
GLOBALink | Chinese cars gain popularity in Botswana
XINHUA
Striking Undulating Walls Transformed this "Living Room" in Shenzhen
Home Journal
GLOBALink | Thai vlogger's journey in south China's Guangxi
XINHUA
(Poster) Xi calls on China, EU to continue see each other as partners
XINHUA
Heatwave hits taxi drivers' wallets in Myanmar
XINHUA
Mideast in Pictures: Group wedding in Gaza Strip
XINHUA
Rockets from Lebanon hit N. Israel, causing power outages
XINHUA
Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting
PR Newswire (美通社)
Xi Jinping, "a sincere friend of Serbia"
XINHUA
Successful Conclusion of SOUEAST Motor Global Investment Promotion Conference: Launching a New Chapter in Globalization Strategy
PR Newswire (美通社)
Revenues of Chinese SOEs up 3.2 pct in first 3 months
XINHUA
Boiling point: André Chiang launches hotpot pop-up in Macau focused on artisanal broths
Tatler Hong Kong
Xinhua News | China sees nearly 300 mln domestic tourist trips during May Day holiday
XINHUA
NetEase to Report First Quarter 2024 Financial Results on May 23
PR Newswire (美通社)
Chinese table tennis players shine in WTT 2024 Saudi Smash
XINHUA
Roundup: U.S. crackdown on pro-Palestinian campus protests denounced
XINHUA
GLOBALink | Journey to France: closer ties bolster China-France bond
XINHUA
Popular destination in China's Guilin attracts May Day holidaygoers
XINHUA
GLOBALink | China, France building up momentum for future-oriented cooperation
XINHUA
留言 1
  • .
    admire
    2020年02月26日15:28
顯示全部